The insomnia is a well-known presenting complaint among substance use disorder patients, as untreated insomnia can lead to major consequences, including is a risk factor for relapse on alcohol/ drugs. Therefore, treatment of this comorbid disorder is indeed important and should be a part of treatment plan while treating an addiction population. The insomnia can be a presenting compliant during acute intoxication and withdrawals period and could persist on chronic basis, which needs to be addressed in a timely manner to avoid adverse consequences. During acute intoxication and withdrawals phase of treatment, main recommendation should be to abstain from the substances that induce it. The medications for insomnia be prescribed only on as needed basis in acute phase of intoxication and withdrawals. If insomnia complaints persist after abstinence from alcohol/drugs, the initial approach should be cognitive and behavioral therapies, which has been proven to address insomnia on long termbasis in a general population. The same approach should be applied to substance use disorder patients, though there is alimited data in regards to those therapeutic approaches in substance abuse population. As per medication management few medications like Benzo-receptor agonist hypnotics (Benzodiazepines and Non-benzodiazepines) should be strongly discouraged secondary to its dependency/tolerance and mortality related issues in substance abuse population. The other FDA approved medications, such as (Ramelteon, Doxepin, Suvorexant) can be preferred over Benzo-receptor agonist medications. In clinical practice the off-label use of Trazodone, Quetiapine, Mirtazapine, Hydroxyzine and Gabapentin is common to treat insomnia in substance users, which at times justify its use, particularly with comorbid psychiatric issues.
Cognitive behavioral therapy for insomnia; Insomnia; Substance use disorder population
CBT-I: Cognitive behavioral therapy for insomnia;
BBT: Brief behavioral therapy;
ICSD3: International classification of sleep disorders;
DSM5: Diagnostic manual of psychiatric disorders 5;
Chronic insomnia disorder patient reports or patients parent or caregiver observes >1 of the following difficulty initiating sleep, maintain sleep, waking up earlier than desired, resistance to go to bed on appropriate schedule, difficulty sleeping without parent or caregiver intervention and patient reports or parent or caregiver observed one or more of following related to nighttime sleep difficulty (Fatigue/ malaise, attention concentration or memory impairment, impaired social, family, occupational or academic performance, mood disturbance/ irritability, day time sleepiness, behavioralproblemssuch as, hyperactivity, impulsivity/ aggression, reduced motivation/ energy/ initiative, prone for errors/ accident, concerns about or dissatisfaction with sleep) . The reported sleep/ wake complaints can’t be purely explained by inadequate opportunity or inadequate circumstances and sleep disturbance and associated sleep daytime symptoms occur at least three time per week for three months and is not better explained by another sleep disorder. Insomnia leads to impair cognitive functioning, negative quality of life measures, increase incidence of bodily pain, poor general health, increase future risk of psychiatric disorders , decrease job performance, increase absenteeism, increase risk of accidents, increased health care cons .
According to ICSD-3 Substances that induced sleep disorders are Alcohol, Opioids, Cannabis, Sedatives, Hypnotics or Anxiolytics, Cocaine, Stimulants, Hallucinogens, Nicotine and Inhalants. As per DSM 5 all above-mentioned substances induce sleep wake cycle disorder.
The mood disorders, anxiety disorders, psychotic disorders, substance use disorders are comorbid with insomnia, The prevalence of drug abuse in insomnia subjects is 4.2% according to one cross sectional study and persistent insomnia predicts future alcohol abuse at 1 year follow up according to that study . Compare to patients without insomnia, patients with insomnia were more likely to report frequent alcohol use for sleep (55% vs. 28%) and relapse to any use of alcohol was much higher in baseline insomnia vs. without baseline insomnia subjects 60% vs. 30% . University of California, Los Angeles gambling sleep study results showed gamblers were 3.5 times more likely to experience a sleep problem compared to individuals who didn’t have gambling problem .
Among insomnia subjects there are areas in brain that don’t deactivate from waking to sleep, like ascending reticular activating system, Hypothalamus, Mesial temporal cortex, Thalamus, Insular cortex . Insomnia is a disorder of hyper arousal, hypothalamus pituitary axis activation, cognitive arousal, sympathetic activation and mood disturbance. There is significant 24-hour increase in cortisol , increased metabolic rate, increased body temperature, increased heart-rate, increased catecholamine, increased EEG high frequency/ low frequency ratio  and hyper metabolism in insomnia patients .
Non-pharmacological approach to treat insomnia
Psychological and behavioral interventions are effective and recommended in the treatment of chronic insomnia. These treatments are effective for adults of all ages. Thetreatmentshould be utilized as an initial intervention when appropriate and conditions permit.
Behavioral and cognitive behavioral therapies demonstrated efficacy in moderate to high quality randomized controlled trials. CBT is as effective as prescription medication for short-termtreatment of insomnia and beneficial effects of CBT in contrast to those produced by medications, may last well beyond the termination of active treatment.
Initial approaches of CBT-I should include at least one behavioral treatment such as stimulus control therapy and or sleep restriction, with or with relaxation . CBT-I is better than pharmacotherapy for insomnia in older subjects at 24 months f/u . Also limited data support CBT-I approach/success in substance users [12,13].
Components of CBT-I: Author Affiliations:Université Laval, Sainte-Foy, Québec (Dr Morin); and Medical College of Virginia/Virginia Commonwealth University, Richmond (Drs Morin, Colecchi, Stone, Sood, and Brink).
Typical CBT-I treatment plan consists of 4-5 session followed by booster session.
Sleep restriction: Particularly effective for patients spending too much time on beds, it improves sleep continuity by limiting time spent in bed to match reported time sleep. Increasessleep drive via sleep deprivation, effective for both sleep onset and maintenance problems. It’s all about sleep efficiency. Normal sleep efficiency is 90-95% in adult population; No one ever sleeps 100% of bedtime. Goal is 85%. Calculate sleep efficiency from sleep diary. Time asleep/ time in bed. Time asleep = Time in bed-(time to fall sleep + time awake at night). Determine patients current, subjective totals sleep time using sleep diaries and history, and establish a fixed awake up time.Work backwards from the desired wake time; determine patient’sbedtime. No sleep is permitted outside of this window. Sleep efficiency is monitored and bedtime is adjusted accordingly .
Sleep diary: is the thermometer of CBT-I, introduced at the end of first assessment visit and completed throughout treatment, reviewed at beginning of each session, essential for successful treatment.
Stimulus control: Considered one of the most effective behavioral treatments, useful for both sleep onset and maintenance problems. It’s based on behavioral principle of classical conditioning. Insomnialeads to stress, anxiety, wakefulness, this takes place in bed, and the bed becomes associated with stress, anxiety and wakefulness . The treatment involves changing the association: worry/wakefulness, waiting, a bed should be a cue for sleep by not sleeping in bed if not asleep. Over one or more nights, sleep drive increases and sleep onset occur more quickly. Over multiple trails, the bed is again associated with rapid sleep onset. The typical instructions are, fixed morning rise times, 7 days a week, regardless of how much you sleep during the night, The bed is only for sleep and sex, no couch napping, only on bed, go to bed when sleepy, leave the bed room if awake for >20 minutes, no clock watching, return to bed only when sleepy, don’t nap in the day. What to do if awake >20 minutes in bed? Leave the bedroom and partake in quiet and sedentary activities, don’t do something where you lose track of time, don’t get too comfortable, don’t give yourself too much light, go to bed when you cant stay up any longer, don’t cook full meal for next day.
Sleep hygiene: Avoid caffeine, nicotine, alcohol, eat a light time bedtime snack, Sleep in quiet dark room, comfortable temperature, good matters, Limit/avoid napping, exercise in afternoon/ early evening. Eat a light bedtime snack to avoid awakening from drop in blood sugar at night .
Worry Time: During the day, schedule a worry time; find a specific place to worry. At night remind yourself you will have time to worry about these things tomorrow (during worry time). Once solutions have been generated, the worry will come up less often when you are in bed at night.
Cognitive therapy: Challenge dysfunctional beliefs about sleep:“I must sleep 8 hours”, correctunrealistic expectations “I should never wake up at night, Reconsider insomnia consequences “Ican’t function without 8 hours of sleep “. These cognitive dysfunctional beliefs require cognitive restructuring to address those automatic negative beliefs regarding sleep .
Internet assisted CBTI: Data suggested that these are affective, particularly when therapists are not available .
Relapse prevention: Relapse is not one bad night, a return of insomnia may be a sign of other psychological distress, insomnia may be a prodromal symptom of depression, alcohol abuse relapse, if insomnia returnsrestrict and control and aim for 5/7 good nights.
Brief behavioral treatment of insomnia BBTI
It is a further modification of CBT-I and includes only four basic steps.
1) Reduce total time in bed;
2) Don’t go to bed unless you are sleepy;
3) Don’t stay in bed unless you are asleep ;
4) Get up at the same time every day of the week, no matter how much you slept the night before .
EBB (comfort band for insomnia)
The first FDA-approved, non-pharmacologic treatment for insomnia, it uses a cooling headband that is supposed to help fall asleep and reach deeper stages of restorative sleep. Several clinical trials support the effectiveness of Ebb. Even though it's just a headband, it requires a prescription to purchase. Ebb is the first and only drug-free solution that uses targeted cooling to reduce metabolic activity in the frontal cortex of the brain, helping to calm mind and body. There is a reduced brain activity and racing mind with Ebbto help reach deeper, more restorative sleep faster.The frontalcortex works overtime in individuals with sleeplessness, creating racing thoughts and making it difficult for the brain to drift naturally into sleep and stay asleep across the night. This racing mind effect is demonstrated via increased metabolic activity in the frontal cortex of the brain . By applying precise, constant cooling to the forehead of individuals with sleeplessness led to significant reductions in metabolic activity in the frontal cortex of the brain. These reductions in activity allowed participants to fall asleep faster and achieve better sleep across the night .
Pharmacological treatment options to treat insomnia
FDA Approved medications: The FDA approved medications are: Benzodiazepine receptor agonist (Benzodiazepines and Non-benzodiazepine hypnotics), Selective melatoninreceptor agonist (Ramelteon 8mg), selective histamine receptor antagonist (Low dose Doxepin 3mg-6mg), and dual orexin/ hypocretin receptor antagonist (Suvorexant 10mg-20mg).
A lot of data is not in favor of Benzodiazepines receptor agonist medications secondary to safety risk, particularly in substance abuse population. In a large cohort of patients attending United Kingdomprime care, anxiolytics and hypnotics drugs were associated with significant mortality over seven years period, after adjusting for a arrange of potential confounders. The dose response association with mortality found for all the these classes of study drugs. (Benzodiazepines, Z drugs (Zaleplon, Zolpidem, Zopiclone) . The fatal toxicity of Zopiclone was not significantly different from that of Benzodiazepines as a group when adjusted for usage . Benzodiazepines receptor agonist binds with Bz1, Bz2 and Bz3 receptors (Non selective). Bz1: hypnotic and amnestic Bz2 and Bz3 antiseizure, and muscle relaxing. Non-benzodiazepine receptor agonists bind with Bz1 GABA receptor only (selective) and act as an allosteric modulator.
Non-FDA approved medications
The non-FDA approved medications for insomnia are: Diphenhydramine (25-100mg qhs), Gabapentin (100-900mg), Hydroxyzine (25-100mg), Melatonin(1-3mg qhs), Mirtazapine (7.5mg-15mg), Trazodone (25-200mg qhs). In clinical practice use of psychotropic for insomnia can be justified, particularly if there is comorbid psychiatric issue, since untreated insomnia can lead to most of psychiatric problems.
The treatment of insomnia should be a part of recovery plan in substance use population;otherwise chance of relapse is higher. Though cognitive/ behavioral therapies are first line recommendation to treat chronic insomnia, its utilization in substance use population as a first line treatment option could be difficult at times secondary to nature of addiction disease. Benzodiazepinesreceptor agonist (benzodiazepine and non-benzodiazepine hypnotics) should be avoided if possible due to avoid risk of dependency/ tolerance/ mortality associated with it. The cognitive and behavioral therapy as an initial treatment plan, with or without medication is still a preferred treatment approach. The treatmentapproaches like use of EBB is available in market and seems to be a reasonable approach to treat insomnia in substance use disorder population as well. Other FDA approved medications like Remelton, Doxepin, Suvorexant should be preferred over Benzodiazepines receptor agonisthypnotics in substance users. The non-FDA approved medications can be prescribedparticularly if there are comorbid psychiatric issues.
Author’s states that this study was not financed.
Both authors contributed equally to this manuscript.
Authors have no conflict of interest.
Citation: Riaz U, Riaz SA (2020) Approach to Treat Insomnia in Substance Use Disorder Population. J Addict Addictv Disord 7: 57.
Copyright: © 2020 Usman Riaz, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.